Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7992-8006

  Liu, Ting ^a   Men, Qiuxu ^a   Wu, Guixian ^a   Yu, Chunrong ^a   Huang, Zan ^a   Liu, Xin ^a   Li, Wenhua ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Autophagy; Differentiation; Leukemia cells; Tetrandrine

Indexed keywords

NOTCH1 RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID RECEPTOR ALPHA; TETRANDRINE; ANTINEOPLASTIC AGENT; BENZYLISOQUINOLINE DERIVATIVE; HERBACEOUS AGENT; NOTCH1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; DRUG EFFECTS; DRUG SCREENING; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BENZYLISOQUINOLINES; CELL DIFFERENTIATION; DRUGS, CHINESE HERBAL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; REACTIVE OXYGEN SPECIES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928398092     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3505     Document Type: Article

References (46)

1. Estey E and Dohner H. Acute myeloid leukaemia. Lancet. 2006; 368(9550):1894-1907.
2. de Thé H and Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature reviews Cancer. 2010; 10(11):775-783.
3. Grignani F, Ferrucci PF, Testa U, Talamo G , Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. cell. 1993; 74(3):423-431.
4. Li X, Xu HL, Liu YX, An N, Zhao S and Bao JK. Autophagy modulation as a target for anticancer drug discovery. Acta pharmacologica Sinica. 2013; 34(5):612-624.
5. Jing Y. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leukemia & lymphoma. 2004; 45(4):639-648.
6. Sawyers C. Targeted cancer therapy. Nature. 2004; 432(7015):294-297.
7. De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Francoijs KJ, Ablain J, Valente S, Castellano R, Goubard A, Collette Y, Mandoli A, Martens JH, de The H, Nebbioso A, et al. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer research. 2014; 74(8):2328-2339.
8. Safa M, Mousavizadeh K, Noori S, Pourfathollah A and Zand H. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. European journal of pharmacology. 2014; 736:115-123.
9. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1998; 72(2):567-572.
10. Lo-Coco F, Awisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.
11. Gianni M, Koken HM, Mounira K. Chelbi-Alix, Gérard Benoit, Michel Lanotte, Zhu Chen and Hugues de Thé. Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. blood. 1998; 91(11):4300-4310.
12. Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval JM, Felipe KB, Kviecinski MR, Verrax J and Calderon PB. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. British journal of cancer. 2014; 111(5):874-882.
13. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology. 2011; 29(5):487-494.
14. Ge DZ, Sheng Y and Cai X. Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines. Scientific reports. 2014; 4:4821.
15. Masciarelli S, Quaranta R, Iosue I, Colotti G, Padula F, Varchi G, Fazi F and Del Rio A. A small-molecule targeting the microRNA binding domain of argonaute 2 improves the retinoic acid differentiation response of the acute promyelocytic leukemia cell line NB4. ACS chemical biology. 2014; 9(8):1674-1679.
16. Watts JM and Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood reviews. 2014; 28(5):205-212.
17. Klionsky DJ, Emr SD. Autophagy as a regulated path-way of cellular degradation. Science. 2000; 290(5497):1717-1721.
18. Levine B. Cell biology: autophagy and cancer. Nature. 2007; 446(7137):745-747.
19. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clinical cancer research. 2009; 15(17):5308-5316.
20. Orfali N, McKenna SL, Cahill MR, Gudas LJ and Mongan NP. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Experimental cell research. 2014; 324(1):1-12.
21. Bavelloni A, Piazzi M, Faenza I, Raffini M, D'Angelo A, Cattini L, Cocco L and Blalock WL. Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acidinduced differentiation of acute promyelocytic leukemia cells. FASEB journal. 2014; 28(5):2009-2019.
22. Jacquel A, Obba S, Boyer L, Dufies M, Robert G, Gounon P, Lemichez E, Luciano F, Solary E and Auberger P. Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood. 2012; 119(19):4527-4531.
23. Wang Z, Cao L, Kang R, Yang M, Liu L, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM and Tang D. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARalpha oncoprotein. Autophagy. 2011; 7(4):401-411.
24. Trocoli A, Bensadoun P, Richard E, Labrunie G, Merhi F, Schlafli AM, Brigger D, Souquere S, Pierron G, Pasquet JM, Soubeyran P, Reiffers J, Segal-Bendirdjian E, Tschan MP and Djavaheri-Mergny M. p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells. Cell death and differentiation. 2014; 21(12):1852-1861.
25. Conway KL, Kuballa P, Khor B, Zhang M, Shi HN, Virgin HW and Xavier RJ. ATG5 regulates plasma cell differentiation. Autophagy. 2013; 9(4):528-537.
26. Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocyte-macrophage differentiation. Blood. 2012; 119(12):2895-2905.
27. Brigger D, Proikas-Cezanne T and Tschan MP. WIPIdependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells. Cell death & disease. 2014; 5:e1315.
28. Xie N, Zhong L, Liu L, Fang Y, Qi X, Cao J, Yang B, He Q and Ying M. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochemical pharmacology. 2014; 89(1):74-85.
29. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127:S5-S16.
30. Liu L, Chao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer research. 2006; 66(24):11851-11858.
31. Schiff PL Jr. Bisbenzylisoquinoline J Nat Prod alkaloids. J Nat Prod. 1987; 50(4):529-599.
32. Gong K, Chen C, Zhan Y, Chen Y, Huang Z and Li W. Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma. The Journal of biological chemistry. 2012; 287(42):35576-35588.
33. Liu C, Gong K, Mao X and Li W. Tetrandrine induces apoptosis by activating reactive oxygen species and repressing Akt activity in human hepatocellular carcinoma. International journal of cancer Journal international du cancer. 2011; 129(6):1519-1531.
34. Wan J, Liu T, Mei L, Li J, Gong K, Yu C and Li W. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. British journal of cancer. 2013; 109(2):342-350.
35. Wang HQ, Liu T, Li L, Wang Q, Yu CR, Liu X and Li WH. Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species. Cell & Bioscience. 2015; 5:4.
36. Nitto T and Sawaki K. Molecular Mechanisms of the Antileukemia Activities of Retinoid and Arsenic. Journal of Pharmacological Sciences. 2014; 126(3):179-185.
37. Wu D, Shao K, Sun J, Zhu F, Ye B, Liu T, Shen Y, Huang H and Zhou Y. Matrine cooperates with all-trans retinoic acid on differentiation induction of all-trans retinoic acidresistant acute promyelocytic leukemia Cells (NB4-LR1): possible mechanisms. Planta medica. 2014; 80(5):399-408.
38. Leontieva OV, Blagosklonny MV. Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression. Aging. 2011; 3 (11):1078-1091.
39. Torgersen ML, Simonsen A. Autophagy:friend or foe in the treatment of fusion protein-associated leukemias?. Autophagy. 2013; 9(12):2175-2177.
40. Yan ZW, Hou JK, He W, Fan L, Huang Y. Chloroquine enhances cobalt chloride-induced leukemic cell differentiation via the suppression of autophagy at the late phase. Biochemical and Biophysical Research Communications. 2013; 430(3):926-932.
41. Wilson A, Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett. 2006; 580(12):2860-2868.
42. Roy A, Haldar S, Basak NP and Banerjee S. Molecular cross talk between Notch1, Shh and Akt pathways during erythroid differentiation of K562 and HEL cell lines. Experimental cell research. 2014; 320(1):69-78.
43. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC and Aster JC. Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling. Molecular and Cellular Biology. 2003; 23(2):655-664.
44. Palomero T and Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(17):5314-5317.
45. Yin DD, Fan FY, Hu XB, Hou LH, Zhang XP, Liu L, Liang YM and Han H. Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562. Leukemia research. 2009; 33(1):109-114.
46. Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V, Biondi A and Comi P. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett. 2005; 219(1):113-120.